HighTower Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

HighTower Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,175	Closed	-$256K	–	3545
2022 Q3	$256K	Sell	26,175 -6,000	-19%	-$58.5K	﹤0.01%	2442
2022 Q2	$313K	Sell	32,175 -325	-1%	-$3.16K	﹤0.01%	2327
2022 Q1	$316K	Sell	32,500 -400	-1%	-$3.88K	﹤0.01%	2491
2021 Q4	$317K	Sell	32,900 -1,000	-3%	-$9.73K	﹤0.01%	2451
2021 Q3	$327K	Buy	+33,900	New	+$331K	﹤0.01%	2358

Other funds holding NKGN

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

HighTower Advisors's NKGN Position: Q4 2022 in Review

HighTower Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 26,175 shares — an estimated $256K sold.

HighTower Advisors first reported a position in NKGN in Q3 2021 and held it in 5 quarters. The position peaked at $327K in Q3 2021. 59 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

HighTower Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
HighTower Advisors sold 26,175 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $256K.
HighTower Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
HighTower Advisors's NKGen Biotech, Inc. Common Stock position peaked at $327K in Q3 2021.
59 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.